| GRAIL INC. DL-,01 |
| USA |
| Gesundheit |
| US3847471014 / A40F8M |
| NL0 (Frankfurt) / GRAL (NASDAQ) |
| FRA:NL0, ETR:NL0, NL0:GR, NASDAQ:GRAL |
| - |
| https://grail.com/ |
|
GRAIL, Inc. is a commercial-stage healthcare company focused on multi-cancer early detection testing and services. Its core offering is Galleri, a blood-based screening test designed to detect multiple cancer types before symptoms appear, supporting ..
>Volltext.. |
| 4215.33 Mio. EUR |
| 3539.36 Mio. EUR |
| 144.45 Mio. EUR |
| -330.8 Mio. EUR |
| -342.28 Mio. EUR |
| -8.52 EUR |
| 79.81 Mio. EUR |
| 48.64 Mio. EUR |
| -257.63 Mio. EUR |
| 10.31 |
| 26.94% |
| 8.81% |
| - |
| - |
| - |
| 2 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 6.575.894 Euro. |
| GRAIL INC, GRAIL INCORPORATED, NASDAQ:GRAL, GRAIL AKTIE |
| 24.09.26 |
|
||||
|
||||
|